Pharmacokinetics and penetration into tissue fluid of ceftizoxime in normal and hyperthermic sheep.
The pharmacokinetics of ceftizoxime was studied in six sheep before and after inducing hyperthermia using Escherichia coli endotoxin. Sheep implanted subcutaneously with cages of non-reactive material for collecting tissue cage fluid (TCF) were used to conduct two trials. In Trial 1 animals with normal basal temperature (normal sheep (NS)) were given intravenous (i.v.) and intramuscular (i.m.) monodoses of ceftizoxime (20mg/kg BW) at 1 week interval. One and 5 weeks later (Trial 2) each sheep were injected 1µg/kg BW of endotoxin to produce hyperthermia (hyperthermic sheep (HS)) previously to i.v. administration (HSi.v.) and i.m. (HSi.m.) of ceftizoxime (20mg/kg BW), respectively. Serum and TCF samples were collected over 6h post-administration. Ceftizoxime concentrations in serum and TCF were determined by a microbiological assay. The concentrations in serum and TCF of ceftizoxime were analyzed through compartmental and non-compartmental models.Rectal temperature were significantly incremented in all animals during Trial 2. The half-time and constant of elimination in serum of ceftizoxime in NSi.v. (t(1/2)=1.1+/-0.4h; lambda(z)=0.7+/-0.2h(-1)) were statistically different those observed in HSi.v. (t(1/2)=1.4+/-0.4h; lambda(z)=0.5+/-0.2h(-1)). The constants of distribution in NSi.v. and HSIV were 5.1+/-4.6 and 4.1+/-3.4h(-1), respectively. The time to reach the maximum concentrations in TCF was latter (p<0.05) in NS (t(max)=2.3+/-0.7h) than in HS (t(max)=1.3+/-0.6 h). After i.m. administration in NS the absorption half-life (0.12+/-0.19h) was latter (p<0.05) than in HS (0.06+/-0.007h) with greater areas under the curve (AUC in NS=65.4+/-20.8 and AUC in HS=34.7+/-7.5 (µg/ml) h). The maximum value of concentration in serum (C(max)) and AUC in TCF were greater (p<0.05) in NS (C(max)=46.1+/-10.6µg/ml and AUC=84.4+/-17.4 (µg/ml) h) as compared to same HS (C(max)=27.0+/-12.9µg/ml and AUC=47.9+/-3.9 (µg/ml) h). The concentrations of ceftizoxime in TCF after i.v. and i.m. in NS and HS were elevated during a 6h period after administration. The bioavailability of ceftizoxime in NS (101.6+/-59.9%) and HS (87.4+/-63.3%) was suitable for its use by the i.m. route.